Brought to you by 
UCB buys Celltech for £1.53bn in cash
03 Jun 2013
Executive Summary
In the largest biotech transaction so far this year, UCB SA has agreed to acquire the approximately 278mm common shares of Celltech Group PLC for £1.53bn ($2.7bn) in cash, or almost six times the company's 2003 sales. Analysts say the merged biopharmaceutical company will rank fifth in sales volume worldwide--following behind Amgen, Novo Nordisk, Schering AG, and Genentech.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com